Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway

• Published in: International journal of molecular sciences Vol. 21; no. 1; p. 360
• Main Authors: Chyau, Charng-Cherng, Wang, Hsueh-Fang, Zhang, Wen-Juan, Chen, Chin-Chu, Huang, Shiau-Huei, Chang, Chun-Chao, Peng, Robert Y
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.01.2020; MDPI
• Subjects: Adiponectin; antrodan; antrodia cinnamomea; Apoptosis; Biological activity; Cholesterol; Diabetes; Fatty liver; Fructose; Glucan; Glucose; hepatoprotective; High fat diet; high-fat-high-fructose diet; Inflammation; Insulin; Insulin resistance; Kinases; Leptin; Lipids; Liver; Liver diseases; Malondialdehyde; Metabolic syndrome; non-alcoholic fatty liver disease (nafld), insulin; Oral administration; orlistat; Oxidative stress; Permeability; Plasma; Plasma levels; SIRT1 protein; Sterol regulatory element-binding protein; Triglycerides; Uric acid; β-Glucan; high-fat-high-fructose diet; Antrodan; orlistat; non-alcoholic fatty liver disease (NAFLD), insulin; Antrodia cinnamomea; hepatoprotective
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21010360

Non-alcoholic fatty liver disease (NAFLD) and -steatohepatitis (NASH) imply a state of excessive fat built-up in livers with/or without inflammation and have led to serious medical concerns in recent years. Antrodan (Ant), a purified β-glucan from . has been shown to exhibit tremendous bioactivity, including hepatoprotective, antihyperlipidemic, antiliver cancer, and anti-inflammatory effects. Considering the already well-known alleviating bioactivity of for the alcoholic steatohepatitis (ASH), we propose that Ant can be beneficial to NAFLD, and that the AMPK/Sirt1/PPARγ/SREBP-1c pathways may be involved in such alleviations. To uncover this, we carried out this study with 60 male C57BL/6 mice fed high-fat high-fructose diet (HFD) for 60 days, in order to induce NAFLD/NASH. Mice were then grouped and treated (by oral administration) as: G1: control; G2: HFD (HFD control); G3: Ant, 40 mgkg (Ant control); G4: HFD+Orlistat (10 mg/kg) (as Orlistat control); G5: HFD+Ant L (20 mg/kg); and G6: HFD+Ant H (40 mg/kg) for 45 days. The results indicated Ant at 40 mg/kg effectively suppressed the plasma levels of malondialdehyde, total cholesterol, triglycerides, GOT, GPT, uric acid, glucose, and insulin; upregulated leptin, adiponectin, pAMPK, Sirt1, and down-regulated PPARγ and SREBP-1c. Conclusively, Ant effectively alleviates NAFLD via AMPK/Sirt1/CREBP-1c/PPARγ pathway.